Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD
Clearmind Medicine Inc. (NASDAQ:CMND) (the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric,
Clearmind Medicine is testing a new medicine called CMND-100 to help people with alcohol problems. This is an early-stage test, so it's too soon to know if it will work, but starting the test is a normal step forward for medicine companies.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.